Open AccessThe short‐term IOP‐lowering effect of brimonidine 0.2% and dorzolomide 2% combination in primary open‐angle glaucoma
Author(s) -
Ermis Sitki Samet,
Ozturk Faruk,
Inan Umit Ubeyt
Publication year - 2002
Publication title -
acta ophthalmologica scandinavica
Language(s) - English
Resource type - Journals
eISSN - 1600-0420
pISSN - 1395-3907
DOI - 10.1034/j.1600-0420.2002.800614.x
Subject(s) - dorzolamide , brimonidine , medicine , intraocular pressure , glaucoma , ophthalmology , latanoprost , open angle glaucoma , ocular hypertension , anesthesia , timolol
. Purpose: To evaluate the ocular hypotensive effect of dorzolamide 2% in primary open‐angle glaucoma (POAG) patients with intraocular pressure (IOP) of at least 22 mmHg despite ongoing twice daily treatment with brimonidine 0.2%. Patients and Methods: Nineteen eyes of 19 patients with POAG and IOP ≥ 22 mmHg, on twice daily brimonidine therapy, were included in the study. Intraocular pressure and adverse effects were recorded on days 2, 7, 14 and 30 after adding dorzolamide three times daily to the treatment. Results: Mean pretreatment IOP was 27.6 ± 2.2 mmHg. This decreased to 24.2 ± 2.2 mmHg after a mean duration of 23.8 ± 12.1 days. After dorzolamide was added to the treatment, mean IOP was 20.8 ± 2.3 mmHg on day 2, 19.3 ± 2.2 mmHg on day 7, 18.0 ± 2.5 mmHg on day 14 and 17.2 ± 2.3 mmHg on day 30. The differences between pre‐ and post‐treatment IOP values were statistically significant (p < 0.0001, anova test). Conclusion: Dorzolamide administered three times daily has significant additive ocular hypotensive effect in POAG patients whose IOP is elevated despite ongoing treatment with brimonidine.